Lupin announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 � Environment Management Systems (EMS), and ISO 45001 � Occupational Health and Safety Management System (OHSMS). This achievement marks a significant milestone in acknowledging Lupin`s commitment to safe and sustainable operations. ISO 14001 is an internationally recognized standard for Environmental Management Systems. This certification demonstrates Lupin`s dedication to minimizing its environmental footprint and fostering sustainable practices across its operations. The ISO 45001 certification underscores Lupin`s unwavering commitment to ensuring the health, safety and well-being of its employees and stakeholders.Powered by Capital Market - Live News

Lupin has granted 5000 stock options of a 2.00 each were granted to an employee of the Company under Lupin Employees Stock Option Plan 2014, with vesting schedule of 25%:25%:25%:25% over four years upon completion of one year from the date of grant. Powered by Capital Market - Live News

Lupin announced that the US Court has lifted the Temporary Restraining Order and denied Astellas` request for a preliminary injunction on Mirabegron ER Tablets. Thereafter, shipment of the product has now resumed. Mirabegron ER Tablets, 25 mg are a generic equivalent of Myrbetriq� Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc., and were launched by Lupin in April 2024. Powered by Capital Market - Live News

Lupin announced the appointment of Jeffrey Kindler and Alfonso �Chito� Zulueta as Independent Directors to its Board. Kindler is an experienced healthcare executive, investor and advisor. He brings over four decades of business experience and has held leadership positions at some of the world`s most recognized companies including Pfizer, where he served as Chairman & Chief Executive Officer, as well as McDonald`s Corporation and General Electric Company. Before that, he was a partner at law firm Williams & Connolly.Kindler is currently CEO of Centrexion Therapeutics, a privately held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute. Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company`s Executive Committee. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council. Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. Powered by Capital Market - Live News

Lupin announced that the Board of Directors of the Company at its meeting held on 6 May 2024, inter alia, have recommended the final dividend of Rs 8 per equity Share (i.e. 400%) , subject to the approval of the shareholders.Powered by Capital Market - Live News